Find and Pitch Jounalists, Get Your Story Covered

Tags: breast cancer,breast cancer brain metastases ,recurrent glioblastoma multiforme ,antibody drug conjugates ,Trop-2

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Libtayo available in Scotland for cervical cancer patients - 12 days ago FDA grants Orphan Drug Designation to Ariceum cancer therapy - 17 days ago CatalYm shows potential of visugromab for treating cachexia - 3 months ago UCB announces MHRA approval for UCB’s Zilbrysq - about 1 year ago
2	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	New Bispecific Shrinks NRG1 Fusion-Positive Lung, Pancreatic Tumors - 18 days ago FDA Approves Zanidatamab for Biliary Tract Cancer - 3 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 6 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 6 months ago FDA Greenlights First Engineered Cell Therapy for a Solid Tumor - 7 months ago Adding Immunotherapy, Anti-TIGIT in First Line Boosts OS in Esophageal Cancer - about 1 year ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - about 1 year ago Tucatinib Regimen Boosts PFS in Advanced HER2-Positive Breast Cancer - about 1 year ago Oncolytic Virus Shows High Response Rates in BCG-Unresponsive Bladder Cancer - about 1 year ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - over 1 year ago Neoadjuvant Cemiplimab Shows Potential as an Option for Cutaneous SCC - over 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - over 1 year ago
3	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr 9 mg and 22 mg Vial Sizes for cGVHD - about 1 month ago FDA Grants Priory Review for Human Monoclonal Antibody Drug to Treat Muscle-Invasive Bladder Cancer - 3 months ago FDA Approves Pembrolizumab Plus Chemotherapy to Treat Metastatic HER2-Negative Gastric, Gastroesophageal Junction Adenocarcinoma - over 1 year ago
4	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric, Gastrosophageal Junction Adenocarcinoma - about 2 months ago FDA Grants Breakthrough Therapy Designation for Nipocalimab to Treat Sjögren Disease - 3 months ago FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 5 months ago FDA Accepts NDA and Priority Review Application for Vimseltinib in Tenosynovial Giant Cell Tumors - 6 months ago FDA Approves Amivantamab-Vmjw and Lazertinib for First-Line Treatment of NSCLC - 6 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 8 months ago FDA Approves Idecabtagene Vicleucel for Multiple Myeloma After 2 or More Lines of Therapy - 11 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 12 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 12 months ago FDA Accepts Supplemental New Drug Application for Adagrasib for Colorectal Cancer - 12 months ago Biosimilar SB8 Is Comparable to Bevacizumab for Non–Small Cell Lung Cancer - about 1 year ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - about 1 year ago FDA Approves Enfortumab Vedotin, Pembrolizumab for Treatment of Urothelial Cancer - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - over 1 year ago
5	John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. Healthcare journalism	Novel Anti-IgG Drug Hits Mark in Sjogren's Patients - 3 months ago
6	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Sequencing in Advanced Urothelial Carcinoma - 4 months ago Adding Tucatinib to T-DM1 Shows PFS Benefit in HER2-Positive Breast Cancer - about 1 year ago T-DXd Could Be 'Practice-Changing' in HER2-Expressing Gynecologic Cancers - about 1 year ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - about 1 year ago Anti-TIGIT Drug Fails to Lift Response Rates in Cervical Cancer Trial - over 1 year ago
7	Judy George MedPage Today Medical reporter, writer. Medical reportingartsliterature	Nipocalimab Shows Sustained Efficacy in Myasthenia Gravis - 4 months ago
8	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Can iTeos and GSK solve TIGIT’s troubles? - 5 months ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 6 months ago FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors - 11 months ago FDA Approves Tislelizumab-jsgr for Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy - 12 months ago
10	Andrew Joseph STAT News Reporter at STAT. Covers health, medicine in Europe. London, England health reportingmedicine	STAT+: FDA approves innovative T cell immunotherapy for rare soft-tissue cancer - 7 months ago STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer - over 1 year ago

Journalists covering sacituzumab govitecan